Autologous hematopoietic transplantation following COVID‐19 infection

Abstract

Abstract Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID‐19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.

Keywords

• autologous transplantation
• COVID‐19
• multiple myeloma